Ключевые слова

2226-5988

2686-6749

Клиническая и экспериментальная морфология

Clinical and Experimental Morphology

ООО "Группа МДВ"

10.31088/cem2026.15.3.15-24

Морфологические и иммуногистохимические маркеры оценки эффективности терапии полифенолами и антоцианами в моделях атопического дерматита

Morphological and immunohistochemical markers for evaluating the effects of polyphenols and anthocyanins in experimental models of atopic dermatitis

Петров

Даниил Иванович

Петров

Даниил Иванович

Petrov

D.I.

fatsplat@mail.ru

0000-0003-2705-1927

Вихарева

Лариса Владимировна

Вихарева

Лариса Владимировна

Vikhareva

L.V.

0000-0001-6864-4417

Матусевич

Сергей Львович

Матусевич

Сергей Львович

Matusevich

S.L.

0009-0005-1517-5764

ФГБОУ ВО Тюменский государственный медицинский университет Минздрава России; ГАУЗ ТО Областной кожно-венерологический диспансер (Тюмень, Россия) Tyumen State Medical University, Tyumen, Russia; Tyumen Regional Dermatology and Venereology Outpatient Clinic, Tyumen, Russia (Tyumen, Russia)

ФГБОУ ВО Тюменский государственный медицинский университет Минздрава России (Тюмень, Россия) Tyumen State Medical University, Tyumen, Russia (Tyumen, Russia)

30 06 2026

2026

15 3 15 24 19 01 2026 16 02 2026 28 01 2026

2026

Коллектив авторов

CC BY-NC 4.0

Атопический дерматит – хронический воспалительный дерматоз, в основе которого лежат комплексное повреждение эпидермального барьера и формирование опосредованного Т-хелперами 2-го типа воспаления. Морфологически это проявляется нарушением терминальной дифференцировки кератиноцитов, перестройкой рогового слоя, снижением экспрессии филаггрина и клаудина-1, а также формированием дермального воспалительного инфильтрата и признаками оксидативного повреждения. Растительные полифенолы, включая антоцианы, рассматриваются как мультитаргетные модуляторы, способные одновременно ослаблять воспалительную активность, усиливать антиоксидантный ответ и поддерживать восстановление барьерных структур эпидермиса. В обзоре систематизированы морфологические и иммуногистохимические маркеры, применяемые в экспериментальных моделях атопического дерматита, приводятся данные о влиянии полифенолов и антоцианов на толщину эпидермиса, выраженность его межклеточного отека, инфильтрацию, содержание барьерных белков и баланс окислительно-восстановительных реакций. Отдельное внимание уделено постановке исследовательской задачи по разработке стандартизованных дерматотропных средств из растительного сырья, включая Epilobium (Chamerion) angustifolium L., и требованиям к доклинической верификации их тканевых эффектов.

Atopic dermatitis is a chronic inflammatory dermatosis characterized by complex impairment of the epidermal barrier and the development of Th2-mediated inflammation. Morphologically, these changes are manifested by disturbed terminal differentiation of keratinocytes, remodeling of the stratum corneum, reduced expression of filaggrin and claudin-1, as well as the formation of a dermal inflammatory infiltrates and signs of oxidative damage. Plant polyphenols, including anthocyanins, are regarded as multi-target modulators capable of simultaneously attenuating inflammatory activity, enhancing the antioxidant defense, and promoting restoration of epidermal barrier structures. This review systematizes the morphological and immunohistochemical markers used in experimental models of atopic dermatitis and summarizes current data on the effects of polyphenols and anthocyanins on epidermal thickness, the severity of epidermal intercellular edema and dermal inflammatory infiltrates, the expression of barrier proteins, and cutaneous redox homeostasis. Special attention is paid to framing Epilobium (Chamerion) angustifolium L. (fireweed) as a promising subject for future research aimed at the development of standardized dermatotropic formulations and the identification of preclinical endpoints, rather than as a source of established evidence of efficacy in experimental models of atopic dermatitis. Keywords: atopic dermatitis, epidermal barrier, filaggrin, claudin-1, Nrf2/HO-1, anthocyanins

Ключевые слова атопический дерматит эпидермальный барьер филаггрин клаудин-1 Nrf2/HO-1 антоцианы

Keywords atopic dermatitis epidermal barrier filaggrin claudin-1 Nrf2/HO-1 anthocyanins

Исследование выполнено в рамках государственного бюджетного финансирования.

The study was carried out within the framework of state budget funding.

Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21–40. DOI: 10.1038/s41573-021-00266-6.

Boguniewicz M. Atopic dermatitis: best of guidelines and yardstick. Allergy Asthma Proc. 2025;46(1):19–25. DOI: 10.2500/aap.2025.46.240087.

Kamata M, Tada Y. Optimal use of Jak inhibitors and biologics for atopic dermatitis on the basis of current evidence. JID Innov. 2023;3(3):100195. DOI: 10.1016/j.xjidi.2023.100195.

Drucker AM, Lam M, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN et al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol. 2024;160(9):936–44. DOI: 10.1001/jamadermatol.2024.2192.

Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregård Øland C, Weidinger S. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022;186(3):440–52. DOI: 10.1111/bjd.20832.

Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047–55. DOI: 10.1001/jamadermatol.2021.3023.

Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–60. DOI: 10.1016/S0140-6736(20)31286-1.

Yoshida T, Beck LA, De Benedetto A. Skin barrier defects in atopic dermatitis: from old idea to new opportunity. Allergol Int. 2022;71(1):3–13. DOI: 10.1016/j.alit.2021.11.006.

Wu S, Pang Y, He Y, Zhang X, Peng L, Guo J et al. A comprehensive review of natural products against atopic dermatitis: flavonoids, alkaloids, terpenes, glycosides and other compounds. Biomed Pharmacother. 2021;140:111741. DOI: 10.1016/j.biopha.2021.111741.

Matsumoto K, Morita H, Nakae S. New insights into human atopic dermatitis provided by mouse models. J Allergy Clin Immunol. 2021;148(3):722–4. DOI: 10.1016/j.jaci.2021.07.016.

Sakamoto K, Nagao K. Mouse models for atopic dermatitis. Curr Protoc. 2023;3(3):e709. DOI: 10.1002/cpz1.709.

Farhan M. The promising role of polyphenols in skin disorders. Molecules. 2024;29(4):865. DOI: 10.3390/molecules29040865.

Li D, Han Y, Zhou J, Chen J, Tey HL, Tan TTY. Flavonoids in atopic dermatitis: mechanisms, delivery innovations, and translational strategies. Front Pharmacol. 2025;16:1631977. DOI: 10.3389/fphar.2025.1631977.

Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. Int J Mol Sci. 2020;21(8):2867. DOI: 10.3390/ijms21082867.

Stefanovic N, Irvine AD. Filaggrin and beyond: new insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives. Ann Allergy Asthma Immunol. 2024;132(2):187–95. DOI: 10.1016/j.anai.2023.09.009.

Upadhyay PR, Seminario-Vidal L, Abe B, Ghobadi C, Sims JT. Cytokines and epidermal lipid abnormalities in atopic dermatitis: a systematic review. Cells. 2023;12(24):2793. DOI: 10.3390/cells12242793.

Sakai T, Hatano Y. Stratum corneum pH and ceramides: key regulators and biomarkers of skin barrier function in atopic dermatitis. J Dermatol Sci. 2025;118(2):51–7. DOI: 10.1016/j.jdermsci.2025.04.001.

Xia Y, Cao H, Zheng J, Chen L. Claudin-1 mediated tight junction dysfunction as a contributor to atopic march. Front Immunol. 2022;13:927465. DOI: 10.3389/fimmu.2022.927465.

Katsarou S, Makris M, Vakirlis E, Gregoriou S. The role of tight junctions in atopic dermatitis: a systematic review. J Clin Med. 2023;12(4):1538. DOI: 10.3390/jcm12041538.

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A et al. Consensus‑based European guidelines for the treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–82. DOI: 10.1111/jdv.14891.

Tanei R, Hasegawa Y. Immunological pathomechanisms of spongiotic dermatitis in skin lesions of atopic dermatitis. Int J Mol Sci. 2022;23(12):6682. DOI: 10.3390/ijms23126682.

Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HC, Chovatiya R et al. Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials. Lancet. 2026;407(10523):53–66. DOI: 10.1016/S0140-6736(25)01865-3.

Trier AM, Kim BS. Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies. Br J Dermatol. 2023;188(6):698–708. DOI: 10.1093/bjd/ljac016.

Luo J, Zhu Z, Zhai Y, Zeng J, Li L, Wang D et al. The role of TSLP in atopic dermatitis: from pathogenetic molecule to therapeutical target. Mediators Inflamm. 2023;2023:7697699. DOI: 10.1155/2023/7697699.

De Simoni E, Candelora M, Belleggia S, Rizzetto G, Molinelli E, Capodaglio I et al. Role of antioxidants supplementation in the treatment of atopic dermatitis: a critical narrative review. Front Nutr. 2024;11:1393673. DOI: 10.3389/fnut.2024.1393673.

Trier AM, Mack MR, Fredman A, Tamari M, Ver Heul AM, Zhao Y et al. IL-33 signaling in sensory neurons promotes dry skin itch. J Allergy Clin Immunol. 2022;149(4):1473–80.e6. DOI: 10.1016/j.jaci.2021.09.014.

Legat FJ. Itch in atopic dermatitis – what is new? Front Med (Lausanne). 2021;8:644760. DOI: 10.3389/fmed.2021.644760.

Zhang Z, Chang C, Xiao L, Su H, Lyu Y, Zhao J et al. The neuro-immune axis in atopic dermatitis: from pathogenic mechanisms to targeted neuroimmunotherapy. J Inflamm Res. 2025;18:18079–113. DOI: 10.2147/JIR.S578036.

Łacwik J, Kraik K, Laska J, Tota M, Sędek Ł, Gomułka K. IL-31/33 axis in atopic dermatitis. Int J Mol Sci. 2025;26(20):10162. DOI: 10.3390/ijms262010162.

Elizalde-Jiménez IG, Ruiz-Hernández FG, Carmona-Cruz SA, Pastrana-Arellano E, Aquino-Andrade A, Romo-González C et al. Global antimicrobial susceptibility patterns of Staphylococcus aureus in atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2024;160(11):1171–81. DOI: 10.1001/jamadermatol.2024.3360.

Kim HB, Alexander H, Um JY, Chung BY, Park CW, Flohr C et al. Skin microbiome dynamics in atopic dermatitis: understanding host-microbiome interactions. Allergy Asthma Immunol Res. 2025;17(2):165–80. DOI: 10.4168/aair.2025.17.2.165.

Wang Z, Hülpüsch C, Traidl-Hoffmann C, Reiger M, Schloter M. Understanding the role of Staphylococcus aureus in atopic dermatitis: strain diversity, microevolution, and prophage influences. Front Med (Lausanne). 2024;11:1480257. DOI: 10.3389/fmed.2024.1480257.

Okamoto H, Li S, Nakamura Y. The role of skin dysbiosis and quorum sensing in atopic dermatitis. JID Innov. 2025;5(4):100377. DOI: 10.1016/j.xjidi.2025.100377.

Hou B, Shao H, Yuan D, Tham EH. Skin and gut microbiome in atopic dermatitis: mechanisms and therapeutic opportunities. Pediatr Allergy Immunol. 2025;36(12):e70265. DOI: 10.1111/pai.70265.

Ogawa T, Ishitsuka Y. The role of the KEAP1-NRF2 system in atopic dermatitis and psoriasis. Antioxidants (Basel). 2022;11(7):1397. DOI: 10.3390/antiox11071397.

Salman S, Paulet V, Hardonnière K, Kerdine-Römer S. The role of NRF2 transcription factor in inflammatory skin diseases. Biofactors. 2025;51(2):e70013. DOI: 10.1002/biof.70013.

Luo Y, Hu J, Zhou Z, Zhang Y, Wu Y, Sun J. Oxidative stress products and managements in atopic dermatitis. Front Med (Lausanne). 2025;12:1538194. DOI: 10.3389/fmed.2025.1538194.

Han SY, Im DS. Evodiamine alleviates 2,4-dinitro-1-chloro-benzene-induced atopic dermatitis-like symptoms in BALB/c mice. Life (Basel). 2024;14(4):494. DOI: 10.3390/life14040494.

Ye S, Zhu L, Ruan T, Jia J, Mo X, Yan F et al. Comparative study of mouse models of atopic dermatitis. Heliyon. 2025;11(2):e41989. DOI: 10.1016/j.heliyon.2025.e41989.

Zheng R, Ren Y, Liu X, He C, Liu H, Wang Y et al. Exogenous drug-induced mouse models of atopic dermatitis. Cytokine Growth Factor Rev. 2024;77:104–16. DOI: 10.1016/j.cytogfr.2024.01.003.

No H, Nam SH, Seo HW, Seo J, Park SH, Kim SB et al. Purple corn extract alleviates 2,4-dinitrochlorobenzene-induced atopic dermatitis-like phenotypes in BALB/c mice. Anim Cells Syst (Seoul). 2021;25(5):272–82. DOI: 10.1080/19768354.2021.1974938.

Dorjsembe B, Nho CW, Choi Y, Kim JC. Extract from black soybean cultivar A63 extract ameliorates atopic dermatitis-like skin inflammation in an oxazolone-induced murine model. Molecules. 2022;27(9):2751. DOI: 10.3390/molecules27092751.

Lv WJ, Huang JY, Li SP, Gong XP, Sun JB, Mao W et al. Portulaca oleracea L. extracts alleviate 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice. Front Nutr. 2022;9:986943. DOI: 10.3389/fnut.2022.986943.

Guo X, He L, Sun J, Ye H, Yin C, Zhang W et al. Exploring the potential of anthocyanins for repairing photoaged skin: a comprehensive review. Foods. 2024;13(21):3506. DOI: 10.3390/foods13213506.

Kim YE, Choi SW, Kim MK, Nguyen TL, Kim J. Therapeutic hydrogel patch to treat atopic dermatitis by regulating oxidative stress. Nano Lett. 2022;22(5):2038–47. DOI: 10.1021/acs.nanolett.1c04899.

Tang KW, Hsu CY, Aljuffali IA, Alalaiwe A, Lai WN, Gu PY et al. Skin delivery of synthetic benzoyl pterostilbenes suppresses atopic dermatitis-like inflammation through the inhibition of keratinocyte and macrophage activation. Biomed Pharmacother. 2024;170:116073. DOI: 10.1016/j.biopha.2023.116073.

Kumkum R, Aston-Mourney K, McNeill BA, Hernández D, Rivera LR. Bioavailability of anthocyanins: whole foods versus extracts. Nutrients. 2024;16(10):1403. DOI: 10.3390/nu16101403.

Dzah CS, Sun Y, Fu Q. Prooxidant behaviour of dietary polyphenols: mechanism and major influencing factors. Adv Red Res. 2024;11:100099. DOI: 10.1016/j.arres.2024.100099.

Kakkar V, Saini K, Singh KK. Challenges of current treatment and future prospects of nanoformulations for atopic dermatitis. Pharmacol Rep. 2023;75(5):1066–95. DOI: 10.1007/s43440-023-00510-3.

Narad P, Gokhale K, Wairka S. Flavonoids-based delivery systems to treat atopic dermatitis. J Drug Deliv Sci Technol. 2024;98:105909. DOI: 10.1016/j.jddst.2024.105909.

Tsvetov N, Pasichnik E, Korovkina A, Gosteva A. Extraction of bioactive components from Chamaenerion angustifolium (L.) Scop. with choline chloride and organic acids natural deep eutectic solvents. Molecules. 2022;27(13):4216. DOI: 10.3390/molecules27134216.

Иринина О.И., Елисеева С.А. Изучение биохимического состава и лечебных свойств растения кипрей узколистный (иван-чай). Ползуновский вестник. 2021;2:44–54. DOI: 10.25712/ASTU.2072-8921.2021.02.006. inina OI, Eliseeva SA. The study of biochemical compo-sition Epilobium angustifolium (fireweed). Polzunovskiy Vestnik. 2021;2:44–54 (In Russ.). DOI: 10.25712/ASTU.2072-8921.2021.02.006.

Nowak A, Zagórska-Dziok M, Perużyńska M, Cybulska K, Kucharska E, Ossowicz-Rupniewska P et al. Assessment of the anti-Inflammatory, antibacterial and anti-aging properties and possible use on the skin of hydrogels containing Epilobium angustifolium L. extracts. Front Pharmacol. 2022;13:896706. DOI: 10.3389/fphar.2022.896706.

Hryć B, Kljakić AC, Cetiz MV, Ak G, Zengin G, Senkardes I et al. Network pharmacology of Epilobium angustifolium metabolites in relation to in vitro analyses of its extracts. Fitoterapia. 2025;183:106552. DOI: 10.1016/j.fitote.2025.106552.

Zawawi NA, Ahmad H, Madatheri R, Fadilah NIM, Maarof M, Fauzi MB. Flavonoids as natural anti-inflammatory agents in the atopic dermatitis treatment. Pharmaceutics. 2025;17(2):261. DOI: 10.3390/pharmaceutics17020261.

Song HK, Park SH, Kim HJ, Jang S, Choo BK, Kim HK et al. Inhibitory effect of Sanguisorba hakusanensis Makino ethanol extract on atopic dermatitis-like responses in NC/Nga mice and human keratinocytes. Sci Rep. 2023;13(1):14594. DOI: 10.1038/s41598-023-41676-3.

Dreger M, Adamczak A, Foksowicz-Flaczyk J. Antibacterial and antimycotic activity of Epilobium angustifolium L. extracts: a review. Pharmaceuticals (Basel). 2023;16(10):1419. DOI: 10.3390/ph16101419.

Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. DOI: 10.1371/journal.pbio.3000410.

Бояринцев Д.И., Кузьминов И.В., Брютова К.В., Русакова О.А. Стандартизация сырья, полученного из надземных органов кипрея узколистного (Chamaenerion angustifolium L.). Химия растительного сырья. 2024;3:177–187. DOI: 10.14258/jcprm.20240312495. Boyarintsev DI, Kuzminov IV, Bryutova KV, Rusakova OA. Standardization of raw materials obtained from aerial or-gans of natural fire-broad (Chamaenerion angustifolium L.). Khimiya Rastielnogo Syrja = Chemistry of Plant Raw Material. 2024;3:177–187 (In Russ.). DOI: 10.14258/jcprm.20240312495.